keyword
MENU ▼
Read by QxMD icon Read
search

Cancer breast cancer oncology

keyword
https://www.readbyqxmd.com/read/28822332/eso-esmo-3rd-international-consensus-guidelines-for-breast-cancer-in-young-women-bcy3
#1
Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, Omalkhair Abulkhair, Maria-João Cardoso, Rebecca Alexandra Dent, Karen Gelmon, Oreste Gentilini, Nadia Harbeck, Anita Margulies, Dror Meirow, Giancarlo Pruneri, Elzbieta Senkus, Tanja Spanic, Medha Sutliff, Luzia Travado, Fedro Peccatori, Fatima Cardoso
The 3rd International Consensus Conference for Breast Cancer in Young Women (BCY3) took place in November 2016, in Lugano, Switzerland organized by the European School of Oncology (ESO) and the European Society of Medical Oncologists (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY2 with incorporation of new evidence to inform the guidelines, and areas of research priorities were identified. This manuscript summarizes the ESO-ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA)...
August 16, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28820525/the-content-validity-of-a-chemotherapy-induced-peripheral-neuropathy-patient-reported-outcome-measure
#2
Ellen M Lavoie Smith, Rylie Haupt, James P Kelly, Deborah Lee, Grace Kanzawa-Lee, Robert Knoerl, Celia Bridges, Paola Alberti, Nusara Prasertsri, Clare Donohoe
PURPOSE/OBJECTIVES: To test the content validity of a 16-item version of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20). 
. RESEARCH APPROACH: Cross-sectional, prospective, qualitative design. 
. SETTING: Six outpatient oncology clinics within the University of Michigan Health System's comprehensive cancer center in Ann Arbor. 
...
September 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28820516/caregiver-reported-health-outcomes-effects-of-providing-reflexology-for-symptom-management-to-women-with-advanced-breast-cancer
#3
Dawn Frambes, Alla Sikorskii, Irena Tesnjak, Gwen Wyatt, Rebecca Lehto, Barbara Given
PURPOSE/OBJECTIVES: To determine the effects of delivering a reflexology intervention on health outcomes of informal caregivers, and to explore whether intervention effects are moderated by caregiver characteristics. 
. DESIGN: Two-group, randomized clinical trial.
. SETTING: Eight oncology clinics in urban and rural regions of Michigan and Illinois.
. SAMPLE: 180 informal caregivers of patients with advanced breast cancer...
September 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28819769/disparities-in-breast-cancer-private-patients-have-better-outcomes-than-public-patients
#4
W C Coetzee, J P Apffelstaedt, T Zeeman, M Du Plessis
INTRODUCTION: Different outcomes in breast cancer have been reported for low and high socio-economic groups. We present data quantifying disparities between South African public and private patients. METHODS: Records of 240 consecutive patients treated in 2008 in a public versus 97 patients in a private health facility were reviewed for demographic and oncologic data. RESULTS: The average of patients was 56.2 versus 51.9 years (p = 0.032)...
August 17, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28817180/preventable-and-mitigable-adverse-events-in-cancer-care-measuring-risk-and-harm-across-the-continuum
#5
Allison Lipitz-Snyderman, David Pfister, David Classen, Coral L Atoria, Aileen Killen, Andrew S Epstein, Christopher Anderson, Elizabeth Fortier, Saul N Weingart
BACKGROUND: Patient safety is a critical concern in clinical oncology, but the ability to measure adverse events (AEs) across cancer care is limited by a narrow focus on treatment-related toxicities. The objective of this study was to assess the nature and extent of AEs among cancer patients across inpatient and outpatient settings. METHODS: This was a retrospective cohort study of 400 adult patients selected by stratified random sampling who had breast (n = 128), colorectal (n = 136), or lung cancer (n = 136) treated at a comprehensive cancer center in 2012...
August 17, 2017: Cancer
https://www.readbyqxmd.com/read/28817175/drug-development-for-breast-colorectal-and-non-small-cell-lung-cancers-from-1979-to-2014
#6
Nancy A Nixon, Omar F Khan, Hasiba Imam, Patricia A Tang, Jose Monzon, Haocheng Li, Gavin Sun, Doreen Ezeife, Sunil Parimi, Scot Dowden, Vincent C Tam
BACKGROUND: Understanding the drug development pathway is critical for streamlining the development of effective cancer treatments. The objective of the current study was to delineate the drug development timeline and attrition rate of different drug classes for common cancer disease sites. METHODS: Drugs entering clinical trials for breast, colorectal, and non-small cell lung cancer were identified using a pharmaceutical business intelligence database. Data regarding drug characteristics, clinical trials, and approval dates were obtained from the database, clinical trial registries, PubMed, and regulatory Web sites...
August 17, 2017: Cancer
https://www.readbyqxmd.com/read/28815749/commentary-estrogen-receptor-expression-in-melanoma
#7
E Ramelyte, P Koelblinger, R Dummer
Sexual hormones share a common cholesterol derived steroid backbone and comprise estrogens, gestagens and androgens. They elicit numerous physiological and pathological functions; e.g. androgens are known to contribute to prostatic cancer development, whereas estrogens are of major importance in the pathogenesis of breast cancer. In 1986, presence of estrogen receptors (ER) on breast cancer cells was described as one of the first biomarkers in oncology [1]. This article is protected by copyright. All rights reserved...
August 16, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28815475/cancer-training-for-frontline-healthcare-providers-in-tanzania
#8
Tara J Rick, Cassondra M Deming, Janey R Helland, Kari A Hartwig
Cervical and breast cancer are responsible for the highest cancer-related mortality in Tanzania, although both are preventable or curable if diagnosed at an early stage. Limited knowledge of cervical cancer by clinic and dispensary level healthcare providers in Tanzania is a barrier for prevention and control strategies. The purpose of the study was to provide basic oncology training to frontline healthcare workers with a focus on cervical and breast cancer in order to increase knowledge. A 1-day cancer training symposium was conducted in Arusha, Tanzania, with 43 clinicians...
August 16, 2017: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/28809079/changes-in-the-use-of-erythropoiesis-stimulating-agents-esas-and-red-blood-cell-transfusion-in-patients-with-cancer-amidst-regulatory-and-reimbursement-changes
#9
Prasad L Gawade, Jesse A Berlin, David H Henry, Dianne Tomita, Barry D Brooks, Janet Franklin, Brian D Bradbury, Cathy W Critchlow
PURPOSE: Evaluate changes in use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in cancer patients receiving myelosuppressive chemotherapy following regulatory and reimbursement actions. METHODS: Calendar year patient cohorts (2005-2013) with breast, colorectal, lung, multiple myeloma, non-Hodgkin lymphoma, ovarian, or prostate cancer and receiving myelosuppressive chemotherapy were identified within the Marketscan database. Incidence of ESA treatment and transfusion were estimated in each year, as was median number of ESA administrations...
August 14, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28807342/accuracy-and-interobserver-agreement-of-retroareolar-frozen-sections-in-nipple-sparing-mastectomies
#10
David A Suarez-Zamora, Luis E Barrera-Herrera, Mauricio A Palau-Lazaro, Fabio Torres-Franco, Alejandro Orozco-Plazas, Lisette Barreto-Hauzeur, Paula A Rodriguez-Urrego
In the last decades, surgical treatment of breast cancer has enormously changed. As a result, nipple-sparing mastectomy (NSM) has evolved as an oncologically safe and cosmetic approach. NSM includes a subareolar frozen section to evaluate malignancy. We determined the accuracy of subareolar frozen section diagnosis, analyzed the discrepancy factor, and estimated the interobserver agreement of frozen section in NSM. A retrospective review of all NSMs at our institution from 2009 to 2015 was performed. Frozen sections were compared to the final diagnoses to analyze the accuracy of subareolar frozen sections...
August 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28806663/management-of-breast-ductal-carcinoma-in-situ-in-catalonia-spain-results-from-the-grup-oncologic-calal%C3%A3-occit%C3%A3-catalonia-survey-with-9-year-follow-up
#11
M J Cambra, B Farrús, F Moreno, Ll Anglada, M Arenas, R Ballester, J Casals, M Cusidó, V García, C Gutiérrez, M Mollà, A Pedro, V Reyes, X Sanz
INTRODUCTION: Reliable data on DCIS incidence and management are not available in many countries. The present study describes the management of DCIS in Catalonia, Spain in the year 2005 and compares these findings to data obtained in France. Local recurrence and late toxicity rates from 2005 through the end of 2014 are reported. MATERIALS AND METHODS: Observational survey of patients with pure DCIS (n = 270) diagnosed during 2005. A written questionnaire, the same as used in the French survey, was completed by 14 doctors at 12 cancer centres in Catalonia, Spain...
August 11, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28802187/radiotherapy-access-in-belgium-how-far-are-we-from-evidence-based-utilisation
#12
Y Lievens, H De Schutter, K Stellamans, M Rosskamp, L Van Eycken
INTRODUCTION: Underutilisation of radiotherapy has been observed worldwide. To evaluate the current situation in Belgium, optimal utilisation proportions (OUPs) adopted from the European SocieTy for Radiotherapy and Oncology - Health Economics in Radiation Oncology (ESTRO-HERO) project were compared to actual utilisation proportions (AUPs) and with radiotherapy advised during the multidisciplinary cancer team (MDT) meetings. In addition, the impact of independent variables was analysed...
August 9, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28801395/the-involvement-of-early-stage-breast-cancer-patients-during-oncology-consultations-in-italy-a-multi-centred-randomized-controlled-trial-of-a-question-prompt-sheet-versus-question-listing
#13
Alessandro Bottacini, Claudia Goss, Maria Angela Mazzi, Alberto Ghilardi, Chiara Buizza, Annamaria Molino, Elena Fiorio, Rolando Nortilli, Vito Amoroso, Lucia Vassalli, Richard F Brown
OBJECTIVES: To investigate, prior to an oncology consultation, the use of a pre-prepared list of evidence based questions, Question Prompt Sheet (QPS), compared with a Question List (QL), a patient self-generated list of questions. DESIGN: Multi-centred, randomised controlled trial. SETTING: Secondary-care patients attending three outpatient oncology clinics in Northern Italy. PARTICIPANTS: 308 women completed the study...
August 11, 2017: BMJ Open
https://www.readbyqxmd.com/read/28799485/monoclonal-antibodies-a-review
#14
Surjit Singh, Nitish Kumar, Pradeep Dwiwedi, Jaykaran Charan, Rimplejeet Kaur, Preeti Sidhu, Vinay Kumar Chugh
Over the last three decades, monoclonal antibodies (MAbs) have made a striking transformation from scientific tools to powerful human therapeutics. Muromonab CD3 a murine MAb, was first FDA approved therapeutic MAb for prevention of kidney transplant rejection. Since its approval in 1986, there has been decline in the further application and approvals until the late 1990s when the first chimeric Mab, Rituximab was approved for the treatment of low grade B cell lymphoma in 1997. With the approval by licensing authorities of chimeric, followed by humanized and then fully human monoclonal antibodies, rate of approval and monoclonal antibodies available in the market for the treatment of various diseases has increased dramatically...
August 9, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28797856/neuropathic-pain-after-breast-cancer-treatment-characterization-and-risk-factors
#15
Susana Pereira, Filipa Fontes, Teresa Sonin, Teresa Dias, Maria Fragoso, José Castro-Lopes, Nuno Lunet
CONTEXT: Neuropathic pain (NP) may be an important contributor to the morbidity burden of breast cancer. OBJECTIVES: We aimed to quantify the incidence of NP in the first year after diagnosis of breast cancer, and to identify its main determinants. METHODS: We performed a prospective cohort study including 506 patients with incident breast cancer, recruited at the Portuguese Institute of Oncology of Porto, and followed for one year; patients with incident NP were additionally evaluated when this condition was diagnosed and after six months, to identify chronic NP...
August 7, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28797847/cytokine-gene-polymorphisms-associated-with-symptom-clusters-in-oncology-patients-undergoing-radiation-therapy
#16
Christine Miaskowski, Yvette P Conley, Judy Mastick, Steven M Paul, Bruce A Cooper, Jon D Levine, Mitchell Knisely, Kord M Kober
CONTEXT: Most of the reviews on the biological basis for symptom clusters suggest that inflammatory processes are involved in the development and maintenance of the symptom clusters. However, no studies have evaluated for associations between genetic polymorphisms and common symptom clusters (e.g., mood disturbance, sickness behavior). OBJECTIVES: Examine the associations between cytokine gene polymorphisms and the severity of three distinct symptom clusters (i...
August 7, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28783425/choosing-wisely-in-oncology-are-we-ready-for-value-based-care
#17
Gabrielle Rocque, Douglas W Blayney, Mohammad Jahanzeb, August Knape, Merry Jennifer Markham, Trang Pham, Jeremy Shelton, Preeti Sudheendra, Tracey Evans
INTRODUCTION: In 2012, ASCO created the Top Five Choosing Wisely (CW) list of low-value tests and procedures for which there is little evidence of benefit. ASCO's Quality Oncology Practice Initiative, an oncologist-led practice-based quality assessment program, includes measures on the basis of these recommendations. METHODS: CW test measures from spring and fall 2013, spring 2014, and spring 2015 were evaluated for concordance rates, change in the concordance over time, and variability by practice characteristics...
August 7, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28781022/determinants-of-last-line-treatment-in-metastatic-breast-cancer
#18
Marika Cinausero, Lorenzo Gerratana, Elisa De Carlo, Donatella Iacono, Marta Bonotto, Valentina Fanotto, Vanessa Buoro, Debora Basile, Maria Grazia Vitale, Karim Rihawi, Gianpiero Fasola, Fabio Puglisi
BACKGROUND: In metastatic breast cancer (MBC) patients, the identification of factors helping clinicians in the choice between active therapy versus best supportive care is needed clinically. The aim of the present study was to identify the clinicopathologic factors that could improve the prognostic valuation of MBC patients and clinical decision-making at the end of life. PATIENTS AND METHODS: The present study analyzed data from a retrospective series of 522 MBC patients treated at the oncology department (University Hospital of Udine) from January 2004 to June 2014...
July 14, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28780190/targeting-eph-ephrin-system-in-cancer-therapy
#19
REVIEW
Alessio Lodola, Carmine Giorgio, Matteo Incerti, Ilaria Zanotti, Massimiliano Tognolini
It is well established that the Eph/ephrin system plays a central role in the embryonic development, with minor implications in the physiology of the adult. However, it is overexpressed and deregulated in a variety of tumors, with a primary involvement in tumorigenesis, tumor angiogenesis, metastasis development, and cancer stem cell regeneration. Targeting the Eph/ephrin system with biologicals, including antibodies and recombinant proteins, reduces tumor growth in animal models of hematological malignancies, breast, prostate, colon, head and neck cancers and glioblastoma...
July 18, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28779846/immune-modulation-by-a-cellular-network-of-mesenchymal-stem-cells-and-breast-cancer-cell-subsets-implication-for-cancer-therapy
#20
Hussam S Eltoukhy, Garima Sinha, Caitlyn A Moore, Oleta A Sandiford, Pranela Rameshwar
The immune modulatory properties of mesenchymal stem cells (MSCs) are mostly controlled by the particular microenvironment. Cancer stem cells (CSCs), which can initiate a clinical tumor, have been the subject of intense research. This review article discusses investigative studies of the roles of MSCs on cancer biology including on CSCs, and the potential as drug delivery to tumors. An understanding of how MSCs behave in the tumor microenvironment to facilitate the survival of tumor cells would be crucial to identify drug targets...
August 1, 2017: Cellular Immunology
keyword
keyword
7548
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"